Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.
Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.
1. Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Contributors - p. Page v 7. Preface - p. Page vi 8. List of Illustrations - p. Page viii 9. List of Tables - p. Page ix 10. Chapter 1 : Overview of changes in the cardiovascular system - p. Page ix 11. Chapter 2 : Cardiovascular disease in cancer survivors: Risk and management - p. Page 9 12. Chapter 3 : Recent trends in cancer immunotherapy: Pathways and inhibitors - p. Page 31 13. Chapter 4 : Stroke risk assessment and atrial fibrillation (AF) in cancer patients - p. Page 46 14. Chapter 5 : Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs - p. Page 61 15. Chapter 6 : Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR - p. Page 79 16. Chapter 7 : Critical insights into cardiotoxicity of anthracyclines - p. Page 97 17. Chapter 8 : Noninvasive cardiovascular imaging techniques - p. Page 110 18. Chapter 9 : Cardiovascular risk induced by radiotherapy - p. Page 136 19. Chapter 10 : Cardiovascular complication from cancer therapy - p. Page 161 20. Chapter 11 : Novel anticancer drugs related to cardiotoxicity - p. Page 185 21. Chapter 12 : Principles of cardiovascular rehabilitation - p. Page 207 22. Chapter 13 : Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications - p. Page 228 23. Index - p. Page 245
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.
Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.
1. Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Contributors - p. Page v 7. Preface - p. Page vi 8. List of Illustrations - p. Page viii 9. List of Tables - p. Page ix 10. Chapter 1 : Overview of changes in the cardiovascular system - p. Page ix 11. Chapter 2 : Cardiovascular disease in cancer survivors: Risk and management - p. Page 9 12. Chapter 3 : Recent trends in cancer immunotherapy: Pathways and inhibitors - p. Page 31 13. Chapter 4 : Stroke risk assessment and atrial fibrillation (AF) in cancer patients - p. Page 46 14. Chapter 5 : Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs - p. Page 61 15. Chapter 6 : Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR - p. Page 79 16. Chapter 7 : Critical insights into cardiotoxicity of anthracyclines - p. Page 97 17. Chapter 8 : Noninvasive cardiovascular imaging techniques - p. Page 110 18. Chapter 9 : Cardiovascular risk induced by radiotherapy - p. Page 136 19. Chapter 10 : Cardiovascular complication from cancer therapy - p. Page 161 20. Chapter 11 : Novel anticancer drugs related to cardiotoxicity - p. Page 185 21. Chapter 12 : Principles of cardiovascular rehabilitation - p. Page 207 22. Chapter 13 : Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications - p. Page 228 23. Index - p. Page 245
